Pharmacogenetics of anthracyclines.

dc.contributor.author	C. Sági, Judit
dc.contributor.author	Kutszegi N
dc.contributor.author	Kelemen A
dc.contributor.author	Fodor LE
dc.contributor.author	Gézsi, András
dc.contributor.author	Kovács, Gábor
dc.contributor.author	Erdélyi, Dániel
dc.contributor.author	Szalai, Csaba
dc.contributor.author	Semsei, Ágnes F
dc.date.accessioned	2016-10-12T09:28:27Z
dc.date.available	2016-10-12T09:28:27Z
dc.date.issued	2016
dc.identifier	84977673695
dc.identifier.citation	pagination=1075-87; journalVolume=17; journalIssueNumber=9; journalTitle=PHARMACOGENOMICS;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/3722
dc.identifier.uri	doi:10.2217/pgs-2016-0036
dc.description.abstract	Anthracyclines constitute a fundamental part of the chemotherapy regimens utilized to treat a number of different malignancies both in pediatric and adult patients. These drugs are one of the most efficacious anticancer agents ever invented. On the other hand, anthracyclines are cardiotoxic. Childhood cancer survivors treated with anthracyclines often undergo cardiac complications which are influenced by genetic variations of the patients. The scientific literature comprises numerous investigations in the subject of the pharmacogenetics of anthracyclines. In this review, we provide a comprehensive overview of this research topic. Genetic variants are proposed targets in the personalized treatment in order to individualize dosing and therefore reduce side effects.
dc.relation.ispartof	urn:issn:1462-2416
dc.title	Pharmacogenetics of anthracyclines.
dc.type	Journal Article
dc.date.updated	2016-10-06T10:03:20Z
dc.language.rfc3066	en
dc.identifier.mtmt	3077031
dc.identifier.wos	000379495200009
dc.identifier.pubmed	27266419
dc.contributor.department	SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution	Semmelweis Egyetem